![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Pfizer, Evotec Team Up to Combat Tissue Fibrosis
Pfizer, Evotec Team Up to Combat Tissue Fibrosis
![pfizerlogo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/pfizerlogo.gif?t=1576044507&width=430)
Pharmaceutical giant Pfizer is joining forces with Evotec in a four-year deal to combat tissue fibrosis.
The research partnership will make use of Germany-based Evotec’s drug discovery platform and Pfizer’s wide network of technologies, drug development and marketing expertise.
The companies will search for innovative treatments to address multi-organ fibrosis, a critical condition with few effective options to reduce life-threatening scarring that can lead to organ failure.
Financial terms of the deal were not disclosed, but include an upfront payment and achievement-based payments related to development and sales milestones.
Evotec, whose focus has been in on kidney fibrosis, views the move as a growth opportunity. Pfizer sees Evotec as well-positioned to create cutting-edge discoveries in several areas of fibrosis. — Victoria Pelham
Upcoming Events
-
21Oct